H. Salih
发表
L. Zekri,
G. Jung,
S. Berchtold,
2023,
Frontiers in Immunology.
R. Schlenk,
A. Kopp-Schneider,
J. Heitmann,
2022,
Pharmaceutical statistics.
Melanie Märklin,
L. Zekri,
G. Jung,
2022,
Frontiers in Immunology.
N. Prakash,
L. Zekri,
G. Jung,
2023,
Molecular therapy : the journal of the American Society of Gene Therapy.
M. Schindler,
L. Zekri,
G. Jung,
2023,
Frontiers in Immunology.
M. Schindler,
K. Wiesmüller,
M. Bitzer,
2023,
medRxiv.
J. Karbach,
J. Reusch,
Malte Roerden,
2021,
Nature.
K. Wiesmüller,
Melanie Märklin,
J. Walz,
2023,
Nature communications.
H. Rammensee,
S. Held,
P. Brossart,
2021,
Cancer discovery.
A Benner,
K. Döhner,
R. Schlenk,
2016,
Blood Cancer Journal.
A. Benner,
K. Döhner,
R. Schlenk,
2019,
Leukemia.
A. Herrmann,
L. Zekri,
G. Jung,
2022,
Cancers.
Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
Melanie Märklin,
J. Kauer,
J. Heitmann,
2022,
Scientific Reports.
K. Döhner,
R. Schlenk,
M. Heuser,
2023,
Journal of Hematology & Oncology.
H. Rammensee,
S. Held,
P. Brossart,
2021
.
Abstract 2078: CLN-049 is a bispecific T cell engaging IgG-like antibody targeting FLT3 on AML cells
P. Baeuerle,
J. Michaelson,
Bochong Li,
2022,
Cancer Research.
A. Hartkopf,
Melanie Märklin,
T. Engler,
2023,
International journal of molecular sciences.
W. Hiddemann,
K. Metzeler,
H. Leonhardt,
2017,
Leukemia.